Welcome to our dedicated page for Nextcure news (Ticker: NXTC), a resource for investors and traders seeking the latest updates and insights on Nextcure stock.
NextCure, Inc. develops targeted cancer therapies as a clinical-stage biopharmaceutical company, with news centered on antibody-drug conjugate programs and related financial updates. Its principal update themes include SIM0505, a Cadherin-6-directed ADC with a topoisomerase 1 inhibitor payload, and LNCB74, a B7-H4-directed ADC.
Company announcements also cover clinical data presentations, FDA interactions such as Fast Track designation for SIM0505 in platinum-resistant ovarian cancer, collaborations with Simcere Zaiming, business updates, financial results, and participation in healthcare investor conferences.
Avere Therapeutics announced a $500 million private placement from a syndicate of healthcare-focused institutional investors to support development of its once-weekly oral IL-23 receptor antagonist AVR-001. This financing is in addition to a previously announced $320 million concurrent private investment.
According to Avere, the two private placements, consisting of common stock and pre-funded warrants, are expected to close immediately prior to the completion of its all-stock merger with NextCure (Nasdaq: NXTC). Upon closing, Avere is expected to have 449,668,672 as-converted shares outstanding, and the combined proceeds are expected to fund its operating plan into 2029. The merged company is expected to operate as Avere Therapeutics and trade on Nasdaq under ticker AVRX.
NextCure (Nasdaq:NXTC) reported second quarter 2026 results and outlined a strategic shift centered on a definitive all‑stock merger with Avere Therapeutics, announced July 14, 2026. Upon closing, the combined company is expected to operate as Avere Therapeutics and trade on Nasdaq under ticker “AVRX”, with existing NextCure stockholders retaining an ownership interest and receiving CVRs tied to specified legacy assets. Concurrently, Avere entered a securities purchase agreement for a private financing expected to raise about $320 million in gross proceeds immediately before closing, subject to customary conditions.
NextCure is restructuring to reduce expenses and preserve capital, including facility footprint reductions and asset sales, while seeking to preserve value in SIM0505 and other assets. Q2 2026 cash, cash equivalents and marketable securities were $20.1 million, down from $41.8 million at December 31, 2025. Q2 research and development expense fell to $7.4 million from $24.1 million, mainly due to prior‑year license fees, and general and administrative expense declined to $2.6 million from $3.2 million. Asset impairment costs tied to restructuring were $5.1 million, contributing to a Q2 net loss of $14.9 million, versus a $26.8 million net loss a year earlier.
NextCure entered a Transition and Continuation Agreement with LigaChem Biosciences, under which LigaChem elected to continue development of ADC candidate LNCB74 as Sole Developing Party while NextCure provides transition support and remains eligible for future milestone and royalty payments. For ADC SIM0505, NextCure has instructed U.S. trial sites to stop screening, consenting and enrolling new patients and is no longer expanding the clinical site footprint, while seeking options to preserve SIM0505’s value for shareholders.
NextCure (Nasdaq: NXTC) and privately held Avere Therapeutics agreed to an all-stock merger that will combine NextCure’s public listing with Avere’s oral IL‑23 program, AVR‑001. The deal is expected to close in the second half of 2026, after which the combined company will operate as Avere Therapeutics and trade on Nasdaq under the ticker “AVRX”.
A concurrent $320 million private placement, including $251 million of convertible notes exchanged into common stock, is expected to fund operations through a global Phase 2b psoriasis readout, and the starts of Phase 3 psoriasis and Phase 2b ulcerative colitis trials. Avere holds ex‑China rights to AVR‑001 under a license from Hansoh, which will receive $120 million in upfront payments, up to $2.18 billion in milestones, and mid‑single to low‑double digit royalties.
NextCure (Nasdaq:NXTC) announced that a replay of its virtual key opinion leader (KOL) event on SIM0505 is now available. The event followed ASCO 2026 dose escalation data from the Phase 1 trial in ovarian cancer and uterine serous carcinoma.
Experts discussed first reported clinical efficacy data for these difficult-to-treat gynecologic cancers.
NextCure (Nasdaq:NXTC) and partner Simcere Zaiming reported positive Phase 1 dose escalation data for SIM0505, an anti-CDH6 ADC, in advanced gynecologic cancers at ASCO 2026.
Among therapeutic-dose patients (4.8–8.0 mg/kg) with ≥12 weeks follow-up, ORR was 55% in gynecologic cancers, 52.9% in ovarian and 66.7% in USC, with favorable overall safety in 59 heavily pretreated patients. A virtual KOL event is scheduled for June 2, 2026 at 8:00 AM ET.
NextCure (Nasdaq: NXTC) reported Q1 2026 results and a business update on May 7, 2026. Key clinical progress: FDA Fast Track designation for SIM0505 in platinum-resistant ovarian cancer, Phase 1 dose-escalation data to be presented at ASCO 2026 on June 1, 2026, and initiation of a dose-optimization study. Cash totaled $29.7M at March 31, 2026, with runway expected into the first half of 2027 through SIM0505 proof-of-concept.
NextCure (Nasdaq: NXTC) and Simcere Zaiming initiated the dose optimization portion of the Phase 1 study of SIM0505, an investigational CDH6-targeting ADC, focused initially on patients with platinum-resistant ovarian cancer (PROC).
The program will expand U.S. and China trial sites and add sites in Canada and Europe. Phase 1 data readout is planned for ASCO 2026.
NextCure (Nasdaq: NXTC) and Simcere will present Phase 1 data for SIM0505, an anti-CDH6 antibody-drug-conjugate (ADC), as a poster at ASCO 2026.
The poster (Abstract #5580, Board 246) will be presented June 1, 2026, by Xiaohua Wu, MD, PhD; the poster will be posted on the company investor site after the session.
NextCure (Nasdaq: NXTC) announced the FDA granted Fast Track designation to SIM0505, an anti-CDH6 antibody-drug conjugate, for treatment of platinum-resistant ovarian cancer.
The company plans to begin dose optimization in Q2 2026 and will present Phase 1 data at ASCO 2026, enabling closer FDA engagement to accelerate development.
NextCure (Nasdaq: NXTC) and Simcere announced that an abstract for SIM0505 (CDH6 ADC) was accepted for presentation at ASCO 2026, held May 29–June 2 in Chicago. SIM0505 is an investigational ADC targeting Cadherin-6 (CDH6) with a proprietary TOPOi payload.
The ongoing open-label Phase 1 study (NCT06792552) is evaluating SIM0505 in advanced solid tumors, including ovarian cancer, with emphasis on platinum-resistant ovarian cancer.